Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
Brock Binkowski, Sauk City, WI (US); Lance P. Encell, Fitchburg, WI (US); Mary Hall, Waunakee, WI (US); Matthew B. Robers, Madison, WI (US); Michael R. Slater, Madison, WI (US); Keith V. Wood, Mount Horeb, WI (US); and Monika G. Wood, Mount Horeb, WI (US)
Assigned to Promega Corporation, Madison, WI (US)
Filed by Promega Corporation, Madison, WI (US)
Filed on Sep. 21, 2023, as Appl. No. 18/471,901.
Application 14/160,282 is a division of application No. 13/287,986, filed on Nov. 2, 2011, granted, now 8,669,103.
Application 18/471,901 is a continuation of application No. 17/332,459, filed on May 27, 2021, granted, now 12,215,375.
Application 17/332,459 is a continuation of application No. 17/011,597, filed on Sep. 3, 2020, granted, now 11,661,623.
Application 17/011,597 is a continuation of application No. 15/948,070, filed on Apr. 9, 2018, granted, now 10,774,364.
Application 15/948,070 is a continuation of application No. 14/160,282, filed on Jan. 21, 2014, granted, now 9,951,373.
Claims priority of provisional application 61/409,422, filed on Nov. 2, 2010.
Prior Publication US 2024/0158831 A1, May 16, 2024
1. A composition comprising a circularly permuted polypeptide having an N-terminal segment linked to a C-terminal segment, wherein the N-terminal segment of the circularly permuted polypeptide has at least 95% sequence identity to a portion of SEQ ID NO: 89 from a circular permutation site to the C-terminus of SEQ ID NO: 89, wherein the C-terminal segment of the circularly permuted polypeptide has at least 95% sequence identity to a portion of SEQ ID NO: 89 from the N-terminus to the circular permutation site of SEQ ID NO: 89, wherein the circular permutation site is within a transition between predicted protein structural motifs of a polypeptide of SEQ ID NO: 89, and wherein the circularly permuted polypeptide exhibits luciferase activity in the presence of a coelenterazine substrate.